Background/Aims: The reasons for lower health-related quality of life (HRQOL) scores in women compared to men on maintenance hemodialysis (MHD) are unknown. We investigated whether depression accounts for gender differences in HRQOL. Methods: Cross-sectional study of 868 (40.9% women) Brazilian MHD patients (PROHEMO Study). We used the Kidney Disease Quality of Life Short Form to assess HRQOL and the Center for Epidemiological Studies Depression (CES-D) scale (scores from 0–60) to assess depression with scores ≧18 indicating high depression probability. Results: Higher depression scores were associated with lower HRQOL in both sexes. Women had higher depression scores; 51.8% of women versus 38.2% of men (p < 0.001) had CES-D scores ≧18. Women scored lower on all 9 assessed HRQOL scales. The female-to-male differences in HRQOL were slightly reduced with inclusion of Kt/V and comorbidities in regression models. Substantial additional reductions in female-to-male differences in all HRQOL scales were observed after including depression scores in the models, by 50.9% for symptoms/problems related to renal failure, by 71.6% for mental health and by 87.1% for energy/vitality. Conclusions: Lower HRQOL among women was largely explained by depression symptoms. Results support greater emphasis on treating depression to improve HRQOL in MHD patients, particularly women.

Lopes AA, Bragg-Gresham JL, Goodkin DA, Fukuhara S, Mapes DL, Young EW, Gillespie BW, Akizawa T, Greenwood RN, Andreucci VE, Akiba T, Held PJ, Port FK: Factors associated with health-related quality of life among hemodialysis patients in the DOPPS. Qual Life Res 2007;16:545–557.
Lopes GB, Martins MT, Matos CM, de Amorim JL, Leite EB, Miranda EA, Lopes AA: Comparações de medidas de qualidade de vida entre mulheres e homens em hemodiálise (in Portugese). Rev Assoc Med Bras 2007;53:506–509.
Kimmel PL: Psychosocial factors in dialysis patients. Kidney Int 2001;59:1599–1613.
Lopes AA, Albert JM, Young EW, Satayathum S, Pisoni RL, Andreucci VE, Mapes DL, Mason NA, Fukuhara S, Wikstrom B, Saito A, Port FK: Screening for depression in hemodialysis patients: associations with diagnosis, treatment, and outcomes in the DOPPS. Kidney Int 2004;66:2047–2053.
Lopes AA, Bragg J, Young E, Goodkin D, Mapes D, Combe C, Piera L, Held P, Gillespie B, Port FK: Depression as a predictor of mortality and hospitalization among hemodialysis patients in the United States and Europe. Kidney Int 2002;62:199–207.
Duarte PS, Ciconelli RM, Sesso R: Cultural adaptation and validation of the ‘Kidney Disease and Quality of Life–Short Form (KDQOL-SF 1.3)’ in Brazil. Braz J Med Biol Res 2005;38:261–270.
Silveira DX, Jorge MR: Propriedades psicométricas da escala de rastreamento populacional para depressão CES-D em populações clínica e não clínica de adolescentes e adultos jovens (in Portugese). Psiq Clin 1998;25:251–261.
Radloff L: The CES-D scale: a self-report depression scale for research in the general population. Appl Psychol Meas 1977;1:385–401.
Hedayati SS, Bosworth HB, Kuchibhatla M, Kimmel PL, Szczech LA: The predictive value of self-report scales compared with physician diagnosis of depression in hemodialysis patients. Kidney Int 2006;69:1662–1668.
Turk S, Atalay H, Altintepe L, Guney I, Okudan N, Tonbul HZ, Gokbel H, Kucur R, Yeksan M, Yildiz A: Treatment with antidepressive drugs improved quality of life in chronic hemodialysis patients. Clin Nephrol 2006;65:113–118.
Zimmermann PR, Camey SA, Mari JJ: A cohort study to assess the impact of depression on patients with kidney disease. Int J Psychiatry Med 2006;36:457–468.
Troidle L, Wuerth D, Finkelstein S, Kliger A, Finkelstein F: The BDI and the SF36: which tool to use to screen for depression? Adv Perit Dial 2003;19:159–162.
Ware JE, Kosinski M, Keller SD: SF-36 Physical and Mental Health Summary Scales: A User’s Manual. Boston, The Health Institute, 1994.
Tietjen GE, Brandes JL, Digre KB, Baggaley S, Martin V, Recober A, Geweke LO, Hafeez F, Aurora SK, Herial NA, Utley C, Khuder SA: High prevalence of somatic symptoms and depression in women with disabling chronic headache. Neurology 2007;68:134–140.
Munce SE, Stewart DE: Gender differences in depression and chronic pain conditions in a national epidemiologic survey. Psychosomatics 2007;48:394–399.
Gottlieb SS, Khatta M, Friedmann E, Einbinder L, Katzen S, Baker B, Marshall J, Minshall S, Robinson S, Fisher ML, Potenza M, Sigler B, Baldwin C, Thomas SA: The influence of age, gender, and race on the prevalence of depression in heart failure patients. J Am Coll Cardiol 2004;43:1542–1549.
Holbrook TL, Hoyt DB: The impact of major trauma: quality-of-life outcomes are worse in women than in men, independent of mechanism and injury severity. J Trauma 2004;56:284–290.
Norris CM, Hegadoren K, Pilote L: Depression symptoms have a greater impact on the 1-year health-related quality of life outcomes of women post-myocardial infarction compared to men. Eur J Cardiovasc Nurs 2007;6:92–98.
Ong L, Irvine J, Nolan R, Cribbie R, Harris L, Newman D, Mangat I, Dorian P: Gender differences and quality of life in atrial fibrillation: the mediating role of depression. J Psychosom Res 2006;61:769–774.
Hankin BL, Abramson LY: Development of gender differences in depression: an elaborated cognitive vulnerability-transactional stress theory. Psychol Bull 2001;127:773–796.
Lunsky Y: Depressive symptoms in intellectual disability: does gender play a role? J Intellect Disabil Res 2003;47:417–427.
Almeida-Filho N, Lessa I, Magalhaes L, Araujo MJ, Aquino E, James SA, Kawachi I: Social inequality and depressive disorders in Bahia, Brazil: interactions of gender, ethnicity, and social class. Soc Sci Med 2004;59:1339–1353.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.